- Samsung Biologics and Eli Lilly have signed a collaboration agreement to establish a Lilly Gateway Labs site in Korea to support early-stage biotechnology companies.
- The five-story, 125,000-square-foot facility at Samsung Biologics’ Bio Campus II is expected to open in July 2027 and host up to 30 companies.
Samsung Biologics has entered a collaboration agreement with Eli Lilly and Company to establish a Lilly Gateway Labs (LGL) site in Korea. The facility will support early-stage and emerging biotechnology companies as they advance scientific research toward development and manufacturing.
The new Gateway Labs site will be located within Samsung Biologics’ Bio Campus II. The five-story building will cover approximately 125,000 square feet and is expected to be completed in July 2027. The facility will include flexible laboratory space, research infrastructure, collaborative work areas, and operational support for up to 30 companies selected jointly by Lilly and Samsung.
Under the agreement, Samsung Biologics will develop and operate the facility, while Lilly Gateway Labs will provide customized scientific engagement to support resident biotechnology companies. The initiative is designed to connect early-stage companies with Lilly’s global network of scientific expertise and resources.
“This collaboration represents a significant step in expanding Gateway Labs’ global reach. Korea has emerged as a vibrant center for life sciences innovation with exceptional scientific talent. By establishing Gateway Labs here, we’re creating a hub where early-stage companies can access the resources, expertise, and connections needed to accelerate their journey from discovery to development, strengthening both local and global biotech innovation.”
Julie Gilmore, Ph.D., vice president, and global head of Lilly Gateway Labs and Catalyze360 Portfolio Management
The project aims to contribute to Korea’s biotechnology ecosystem by supporting startup companies, fostering collaboration, and connecting domestic and international innovators with global industry expertise. Lilly Gateway Labs, part of Lilly Catalyze360, provides laboratory space, technology access, and research and development capabilities to help biotechnology companies accelerate drug discovery and development.
